Humana (NYSE:HUM) Given New $268.00 Price Target at TD Cowen

Humana (NYSE:HUM) had its target price increased by equities researchers at TD Cowen from $261.00 to $268.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has a “hold” rating on the insurance provider’s stock. TD Cowen’s target price suggests a potential upside of 5.28% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 price target on shares of Humana in a research report on Tuesday, October 1st. Bank of America downgraded Humana from a “neutral” rating to an “underperform” rating and lowered their price target for the stock from $376.00 to $247.00 in a research report on Wednesday, October 2nd. Barclays increased their price target on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. increased their price target on Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, nineteen have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $312.95.

Humana Stock Performance

Humana stock traded down $6.16 during midday trading on Monday, hitting $254.55. 1,019,697 shares of the company were exchanged, compared to its average volume of 1,852,119. The firm has a market capitalization of $30.65 billion, a PE ratio of 22.57, a price-to-earnings-growth ratio of 2.00 and a beta of 0.52. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $527.18. The business has a fifty day simple moving average of $297.06 and a two-hundred day simple moving average of $334.52. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.66 and a current ratio of 1.76.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, sell-side analysts forecast that Humana will post 16.1 earnings per share for the current year.

Institutional Investors Weigh In On Humana

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUM. Pzena Investment Management LLC increased its stake in Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after acquiring an additional 1,955,375 shares during the last quarter. Ontario Teachers Pension Plan Board increased its stake in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after acquiring an additional 1,050,459 shares during the last quarter. Marshall Wace LLP increased its stake in Humana by 118.9% during the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after acquiring an additional 774,085 shares during the last quarter. International Assets Investment Management LLC increased its stake in Humana by 261,025.1% during the third quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after acquiring an additional 738,701 shares during the last quarter. Finally, Steadfast Capital Management LP acquired a new stake in Humana during the first quarter worth $158,813,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.